December 2022 OSE Immunotherapeutics Announces Latest Preclinical Efficacy Data on its Anti-IL-7 Receptor Antagonist OSE-127 in Acute Lymphoblastic Leukemia at the 2022 American Society of Hematology (ASH) Annual Meeting
November 2022 OSE Immunotherapeutics Announces Publication of Peer-Reviewed Data on CLEC-1, its Novel Myeloid Immune Checkpoint in ‘Science Advances’
November 2022 OSE Immunotherapeutics Builds a Strong R&D Strategy Through Innovative First-in-Class Multi-Platform Programs
November 2022 OSE Immunotherapeutics Announces Award for OSE-127’s Upcoming Oral Presentation in Acute Lymphoblastic Leukemia at the 2022 American Society of Hematology (ASH) Annual Meeting
November 2022 Servier and OSE Immunotherapeutics announce completion of patient enrollment in the Phase 2a clinical trial of OSE-127/S95011 in primary Sjögren’s syndrome
October 2022 OSE Immunotherapeutics Updates on Tedopi®, a Cancer Vaccine as Potential New Standard of Care in Non-Small Cell Lung Cancer After Failure to Immunotherapies
October 2022 OSE Immunotherapeutics Presents Update on BiCKI®-IL-7v and CLEC-1 Immuno-Oncology Programs at International Conferences